Inhibition of these CDKs may be particularly important for tumours relying on altered transcriptional regulation, such as those driven by oncogenic transcription factors like breast (MYC) and prostate (AR) cancers and Ewing sarcomas (EWS‐FLI1). This evidence concerns the gene MYC and cancer.